Tolerogenic vaccines for Multiple Sclerosis
Author
Mannie, Mark D.; Curtis II, Alan Dale
Abstract
Tolerogenic vaccines represent a new class of vaccine designed to re-establish immunological tolerance, restore immune homeostasis, and thereby reverse autoimmune disease. Tolerogenic vaccines induce long-term, antigen-specific, inhibitory memory that blocks pathogenic T cell responses via loss of effector T cells and gain of regulatory T cell function. Substantial advances have been realized in the generation of tolerogenic vaccines that inhibit experimental autoimmune encephalomyelitis in a preclinical setting, and these vaccines may be a prequel of the tolerogenic vaccines that may have therapeutic benefit in Multiple Sclerosis. The purpose here is to provide a snapshot of the current concepts and future prospects of tolerogenic vaccination for Multiple Sclerosis, along with the central challenges to clinical application.
Date
2013-05
Citation:
APA:
Mannie, Mark D., & Curtis II, Alan Dale. (May 2013).
Tolerogenic vaccines for Multiple Sclerosis.
Human Vaccines & Immunotherapeutics,
9(5),
1032-
1038. Retrieved from
http://hdl.handle.net/10342/5655
MLA:
Mannie, Mark D., and Curtis II, Alan Dale.
"Tolerogenic vaccines for Multiple Sclerosis". Human Vaccines & Immunotherapeutics.
9:5. (1032-1038),
May 2013.
December 10, 2023.
http://hdl.handle.net/10342/5655.
Chicago:
Mannie, Mark D. and Curtis II, Alan Dale,
"Tolerogenic vaccines for Multiple Sclerosis," Human Vaccines & Immunotherapeutics 9, no.
5 (May 2013),
http://hdl.handle.net/10342/5655 (accessed
December 10, 2023).
AMA:
Mannie, Mark D., Curtis II, Alan Dale.
Tolerogenic vaccines for Multiple Sclerosis. Human Vaccines & Immunotherapeutics.
May 2013;
9(5):
1032-1038.
http://hdl.handle.net/10342/5655. Accessed
December 10, 2023.
Collections